What is the appropriate management of chronic urticaria in children, including dosing of second‑generation H1 antihistamines and subsequent therapy options?

Management of Chronic Urticaria in Children

Start with a standard dose of second-generation H1-antihistamines, and if symptoms remain uncontrolled after 2-4 weeks, increase the dose up to 4-fold before adding omalizumab as second-line therapy. 1

First-Line Treatment: Second-Generation H1-Antihistamines

The 2022 international urticaria guidelines establish a clear, streamlined 3-step treatment algorithm that applies to children with chronic urticaria 1:

Initial Dosing

• Begin with standard-dose second-generation H1-antihistamines (weight-adjusted for children)
• Examples include cetirizine, levocetirizine, fexofenadine, bilastine, desloratadine, and rupatadine
• Assess response after 2-4 weeks (or earlier if symptoms are intolerable)

Up-Dosing Strategy

If inadequate control occurs, increase the antihistamine dose up to 4-fold the standard dose 1. This is critical because:

• Approximately 66-78% of children respond to antihistamines at standard or increased doses 2, 3
• Children generally respond better to antihistamines than adults 4
• Most children who respond to up-dosing achieve control with double the standard dose—efficacy appears limited beyond 2-fold dosing in pediatric populations 2

Important caveat: The frequency of urticaria >4 days per week predicts failure of standard-dose antihistamines (OR 4.36), so consider earlier up-dosing in these patients 5.

Specific Antihistamine Recommendations for Up-Dosing

Based on safety and efficacy data 6:

• Grade A recommendation (safest for up-dosing to 4x): Bilastine, levocetirizine, fexofenadine
• Cetirizine: Effective but may cause dose-related sedation at higher doses—use cautiously
• Rupatadine and cetirizine: Only antihistamines with documented pediatric up-dosing safety data 6

Step-Down Protocol

Once complete control is achieved (maintain for at least 3 consecutive months):

• Reduce dose by no more than 1 tablet per month
• If breakthrough symptoms occur, return to the last effective dose
• This "as much as needed, as little as possible" approach minimizes treatment burden and assesses for spontaneous remission 1

Second-Line Treatment: Omalizumab

Add omalizumab if symptoms remain inadequately controlled despite up-dosed antihistamines 1:

Dosing

• Start with 300 mg subcutaneously every 4 weeks
• Allow up to 6 months for response assessment
• If insufficient response: Consider up-dosing to 600 mg every 2 weeks (maximum dose) 1
• Higher doses are particularly beneficial in patients with high body mass index 1

Efficacy in Children

• All children treated with omalizumab in recent studies responded 3
• Excellent efficacy and safety profile in pediatric populations 4
• Should not be delayed if antihistamines fail—prolonged ineffective antihistamine therapy delays disease control 7

Third-Line Treatment: Cyclosporine

For patients who fail omalizumab, add cyclosporine 1:

Dosing and Monitoring

• Dose: Up to 5 mg/kg body weight daily
• Monitor blood pressure and renal function (BUN, creatinine) every 6 weeks 1

Important Safety Considerations

Cyclosporine carries significant risks 1:

• Hypertension
• Renal failure
• Hirsutism and gum hypertrophy
• Risk of epilepsy in predisposed patients

The risk-benefit profile of high-dose omalizumab is superior to cyclosporine, making it essential to optimize omalizumab therapy before advancing to cyclosporine 1.

Adjunctive Therapies

Short-Course Corticosteroids

• 3-day course of systemic corticosteroids for severe exacerbations (e.g., prednisolone 50 mg daily in adults, weight-adjusted in children) 8, 3
• Successfully used for acute flares in pediatric studies 3
• Long-term corticosteroids should NOT be used except in very selected cases under specialist supervision 8

Montelukast

• Not recommended—showed no benefit in pediatric studies 3
• May benefit aspirin-sensitive or autoimmune urticaria in adults, but response is unpredictable 8

Emerging Therapies

Dupilumab has been approved for chronic spontaneous urticaria in some countries and represents a potential treatment option for refractory cases 4.

Common Pitfalls to Avoid

1. Prolonging ineffective antihistamine therapy: If standard and up-dosed antihistamines fail after 2-4 weeks, escalate to omalizumab promptly 7
2. Using first-generation antihistamines: These are no longer recommended due to sedation and anticholinergic effects
3. Routine extensive laboratory testing: Not indicated unless clinical suspicion exists for specific comorbidities 3
4. Combining multiple antihistamines: Up-dose a single agent rather than adding a second antihistamine
5. Premature step-down: Wait at least 3 months of complete control before reducing doses 1

Special Considerations in Children

• Chronic urticaria in children has a high resolution rate within 2 years (45.9% resolved within 3 years in one study) 4, 3
• Monitor for comorbidities: thyroid autoimmune disease and celiac disease may be diagnosed during chronic urticaria workup 3
• Pregnancy considerations: Avoid all antihistamines if possible, especially first trimester; chlorphenamine often chosen for safety record if treatment necessary 8